Companies / BSX vs SOLV
BSX vs SOLV: Boston Scientific and Solventum
Boston Scientific (BSX) reported $20.1B in revenue against a 14.4% net margin, while Solventum (SOLV) reported $8.3B at a 18.7% net margin, most recently.
| Metric | BSX | SOLV |
|---|---|---|
| Revenue | $20.1B | $8.3B |
| Net Income | $2.9B | $1.6B |
| Gross Margin | 69.0% | 53.5% |
| Operating Margin | 18.0% | 26.2% |
| EPS (Diluted) | $1.94 | $8.88 |
| Free Cash Flow | $3.7B | $-10.0M |
| Total Debt | $11.4B | $5.0B |
| P/E Ratio | 49.2× | 8.9× |
| P/B Ratio | n/m | 2.7× |
| Stock Price | $44.62 | $87.11 |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| BSX Revenue | $12.7B | $14.2B | $16.7B | $20.1B |
| SOLV Revenue | $8.1B | $8.2B | $8.3B | $8.3B |